Kalvista Pharmaceuticals, Inc. has announced the appointment of Benjamin L. Palleiko as its new Chief Executive Officer and a director of the company, effective immediately. Palleiko, who has been with the company since 2016 and previously held the positions of President, Chief Business Officer, and Chief Financial Officer, is taking over as the company prepares to transition into a commercial entity.
The company also revealed that Andrew Crockett has submitted his resignation as CEO and a director of the company. This move comes as Kalvista prepares for the potential launch of Sebetralstat, its oral, on-demand therapy for hereditary angioedema (HAE), following the success of the Konfident phase 3 trial.
Palleiko's appointment is seen as a strategic move as the company gears up for regulatory filings. Kalvista anticipates submitting a new drug application (NDA) to the U.S. FDA for Sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in the same year.
The transition to a commercial organization is further supported by the company's recent positive phase 3 data and successful financing. Kalvista is in a strong position to advance its plans for Sebetralstat on an accelerated timeline as it seeks to launch it broadly for the benefit of people worldwide living with HAE.
This shift in leadership and strategic focus marks a significant juncture for Kalvista Pharmaceuticals, signaling its evolution from a UK-based private research entity to a multinational pre-commercial organization preparing multiple regulatory approval filings for its innovative therapies.
Following these announcements, the company's shares moved -2.7%, and are now trading at a price of $13.99. For the full picture, make sure to review KalVista Pharmaceuticals's 8-K report.
